← Back to patent-cliff list
CAS 90600-20-7
(S,E)-2-((tert-butoxycarbonyl)amino)pent-3-enoic acid(S)-N-Boc-allylglycine
Codes: IXAB-022, ANID-020, (I)796686-1-a
Application context (from source-drug indications)
Breast cancerIxabepiloneMetastatic breast cancerIxabepiloneCervical cancerIxabepiloneProstate cancerIxabepiloneSolid tumourIxabepiloneNeutropeniaIxabepiloneCandidiasisAnidulafunginCandidaemiaAnidulafunginFungal infectionAnidulafunginPeritonitisAnidulafunginAbscessAnidulafunginRespiratory tract infectionAnidulafungin侵袭性念珠菌病Rezafungin acetateCandidiasisRezafungin acetateCandidaemiaRezafungin acetate卡氏肺囊虫感染Rezafungin acetate侵袭性真菌感染Rezafungin acetateAspergillus infectionRezafungin acetate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ixabepilone | Tier C — Watch / trade | - |
| Anidulafungin | Tier C — Watch / trade | - |
| Rezafungin acetate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methylpropionamide→5-bromopent-1-ene→(S)-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N,2-dimethylhept-6-enamide→(1S,2S)-1-(((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)(methyl)amino)-2-methylhept-6-en-1-ol→(S)-2-methylhept-6-enal→3-((tert-butyldimethylsilyl)oxy)-4,4-dimethyl-5-oxoheptanoic acid→(3S,6R,7S,8S)-3-((tert-butyldimethylsilyl)oxy)-7-hydroxy-4,4,6,8-tetramethyl-5-oxotridec-12-enoic acid→(S,1E,5E)-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-amine→(3S,6R,7S,8S)-3-((tert-butyldimethylsilyl)oxy)-7-hydroxy-4,4,6,8-tetramethyl-N-((S,1E,5E)-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-yl)-5-oxotridec-12-enamide→(4S,7R,8S,9S,16S,Z)-4-((tert-butyldimethylsilyl)oxy)-8-hydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→(4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→morpholine→isobutyraldehyde→4-(2-methylprop-1-en-1-yl)morpholine→(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl pentanoate→2,2-dimethyl-3-oxopentanal→allylbis(4,6,6-trimethylbicyclo[3.1.1]hept-2-en-3-yl)borane→tert-butyldimethylsilyl trifluoromethanesulfonate→5-((tert-butyldimethylsilyl)oxy)-4,4-dimethyloct-7-en-3-one→3-((tert-butyldimethylsilyl)oxy)-4,4-dimethyl-5-oxoheptanal→(S,E)-2-aminopent-3-enoic acid→(S,E)-2-((tert-butoxycarbonyl)amino)pent-3-enoic acid→tert-butyl (S,E)-(1-(methoxy(methyl)amino)-1-oxopent-3-en-2-yl)carbamate→tert-butyl (S,E)-(2-oxohept-5-en-3-yl)carbamate→((2-methylthiazol-4-yl)methyl)diphenylphosphine oxide→tert-butyl ((S,1E,5E)-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-yl)carbamate→methoxybis(4,6,6-trimethylbicyclo[3.1.1]hept-2-en-3-yl)borane
(S)-N-Boc-allylglycine→Allylamine→tert-Butyl [(2S)-1-oxo-1-[(prop-2-en-1-yl)amino]pent-4-en-2-yl]carbamate→tert-Butyl [(3S)-2-oxo-1,2,3,4-tetrahydropyridin-3-yl]carbamate→tert-Butyl [(3S,5R,6R)-5,6-dihydroxy-2-oxopiperidin-3-yl]carbamate→(4R,5R)-N2-(tert-Butoxycarbonyl)-4,5-dihydroxy-L-ornithine→(4R,5R)-N2-(tert-Butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-4,5-dihydroxy-L-ornithine→(4R,5R)-4,5-Bis(acetyloxy)-N2-(tert-butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-ornithine→Resin bound (4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-ornithine→(3S,4S)-N-Fmoc-3-acetoxy-4-methyl-L-proline→Resin bound N5-[(3S,4S)-3-(acetyloxy)-1-[[(9H-fluoren-9-yl)oxy]carbonyl]-4-methyl-L-prolyl]-(4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-L-ornithine→O-Acetyl-N-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-threonine→Resin bound N5-[O-acetyl-N-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-threonyl-(3S,4S)-3-(acetyloxy)-4-methyl-L-prolyl]-(4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-L-ornithine
(S)-N-Boc-allylglycine→Allylamine→tert-Butyl [(2S)-1-oxo-1-[(prop-2-en-1-yl)amino]pent-4-en-2-yl]carbamate→tert-Butyl [(3S)-2-oxo-1,2,3,4-tetrahydropyridin-3-yl]carbamate→tert-Butyl [(3S,5R,6R)-5,6-dihydroxy-2-oxopiperidin-3-yl]carbamate→(4R,5R)-N2-(tert-Butoxycarbonyl)-4,5-dihydroxy-L-ornithine→(4R,5R)-N2-(tert-Butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-4,5-dihydroxy-L-ornithine→(4R,5R)-4,5-Bis(acetyloxy)-N2-(tert-butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-ornithine→Resin bound (4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-ornithine→(3S,4S)-N-Fmoc-3-acetoxy-4-methyl-L-proline→Resin bound N5-[(3S,4S)-3-(acetyloxy)-1-[[(9H-fluoren-9-yl)oxy]carbonyl]-4-methyl-L-prolyl]-(4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-L-ornithine→O-Acetyl-N-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-threonine→Resin bound N5-[O-acetyl-N-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-threonyl-(3S,4S)-3-(acetyloxy)-4-methyl-L-prolyl]-(4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-L-ornithine→3(4)-(Pentyloxy)-N-[(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-2,11,12,15-tetrahydroxy-6,20-bis[(1R)-1-hydroxyethyl]-23-[(4S,5S)-5-(4-hydroxyphenyl)-2-phenyl-1,3,2-dioxaborolan-4-yl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl][1(1),2(1):2(4),3(1)-terphenyl]-1(4)-carboxamide
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | (S)-2-((tert-butoxycarbonyl)amino)pent-4-enoic acid Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.